Kailera Therapeutics, Inc. (KLRA)
10.84
-0.49
(-4.32%)
USD |
NASDAQ |
Oct 13, 14:59
Kailera Therapeutics Enterprise Value : 562.07M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 562.07M |
| October 09, 2026 | 598.37M |
| October 08, 2026 | 389.68M |
| October 07, 2026 | 458.38M |
| October 06, 2026 | 497.26M |
| October 05, 2026 | 498.56M |
| October 02, 2026 | 440.23M |
| October 01, 2026 | 523.19M |
| September 30, 2026 | 573.74M |
| September 29, 2026 | 518.00M |
| September 28, 2026 | 534.85M |
| September 25, 2026 | 547.17M |
| September 24, 2026 | 646.33M |
| September 23, 2026 | 795.39M |
| September 22, 2026 | 751.32M |
| September 21, 2026 | 647.62M |
| September 18, 2026 | 756.50M |
| September 17, 2026 | 768.17M |
| September 16, 2026 | 739.65M |
| September 15, 2026 | 836.87M |
| September 14, 2026 | 875.76M |
| September 11, 2026 | 900.38M |
| September 10, 2026 | 1.026B |
| September 09, 2026 | 1.017B |
| September 08, 2026 | 1.223B |
| Date | Value |
|---|---|
| September 04, 2026 | 1.197B |
| September 03, 2026 | 1.134B |
| September 02, 2026 | 1.148B |
| September 01, 2026 | 1.221B |
| August 31, 2026 | 1.090B |
| August 28, 2026 | 1.195B |
| August 27, 2026 | 1.495B |
| August 26, 2026 | 1.484B |
| August 25, 2026 | 1.394B |
| August 24, 2026 | 1.237B |
| August 21, 2026 | 1.319B |
| August 20, 2026 | 1.357B |
| August 19, 2026 | 1.468B |
| August 18, 2026 | 1.405B |
| August 17, 2026 | 1.493B |
| August 14, 2026 | 1.419B |
| August 13, 2026 | 1.423B |
| August 12, 2026 | 1.503B |
| August 11, 2026 | 1.539B |
| August 10, 2026 | 1.554B |
| August 07, 2026 | 1.512B |
| August 06, 2026 | 1.539B |
| August 05, 2026 | 1.449B |
| August 04, 2026 | 1.441B |
| August 03, 2026 | 1.339B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Twist Bioscience Corp. | 9.444B |
| Prime Medicine, Inc. | 669.87M |
| GRAIL, Inc. | 5.365B |
| Arrowhead Pharmaceuticals, Inc. | 8.346B |
| Oncolytics Biotech, Inc. | 55.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -111.31M |
| Total Expenses (Quarterly) | 111.31M |
| EPS Diluted (Quarterly) | -0.8587 |
| Earnings Yield | -15.60% |